Louis-Jeantet Prize for Medicine

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Retrieved on: 
星期四, 一月 25, 2024
EMBO Gold Medal, Professional, Heinz, Max Planck Society, CSO, University Medical Center, I&I, Louis-Jeantet Prize for Medicine, UMG, German, Antiviral Research, Psoriasis, WLA, Animal welfare, Creativity, Inflammation, VHH, Pharmaceutical industry

JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.

Key Points: 
  • JERUSALEM, Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, congratulates the Company's co-lead scientific research collaborator Professor Dr. Dirk Görlich on being awarded the 2024 Louis-Jeantet Prize.
  • Görlich serves as a director of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • According to MPI-NAT, Görlich has received several other scientific awards including the Heinz Maier-Leibnitz Prize, the EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022, and the Animal Welfare Research Prize of the German Federal Ministry of Food and Agriculture.
  • Amir Reichman, Scinai's CEO, commented, "On behalf of Scinai's team, I offer sincere congratulations to Dirk on being awarded the 2024 Louis-Jeantet Prize.

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
星期三, 十一月 15, 2023
MSD, DRS, Broad Institute, DNA, Limited partnership, National academy, Dana–Farber Cancer Institute, Patient, Research, Ubiquitin, Pharmacology, Therapy, Chromatin, Pioneer, Drug discovery, Cancer, Diabetes, Harvard University, Field, Howard Hughes Medical Institute, Translation, Organization, MIT, European, Jude the Apostle, Merck & Co., Austrian Academy of Sciences, Max Planck Society, Translational medicine, Leibniz Prize, JDRF, Pancreatic cancer, Ernst Jung Prize, Biochemistry, SAB, EMBO, Publishing, Louis-Jeantet Prize for Medicine, Pharmacia, Glioblastoma, Boehringer Ingelheim, Medicine, Biotechnology, Genomics, Doctor of Philosophy, Monroe Dunaway Anderson, Biology, DNA repair, Pharmaceutical industry, Science, Merck

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of Native Mass Spectrometry in Drug Discovery by Capturing GPCR Signalling in Native Membrane Environment

Retrieved on: 
星期三, 四月 6, 2022
Medicine, Therapy, Lipid, Degenerative disease, National academy, University, Royal, GPCR, Royal Society, University of Oxford, European Chemical Society, Research, Rhodopsin, Louis-Jeantet Prize for Medicine, Kavli Foundation (United States), Drug discovery, Science, Commander (order), Industry, Technology, Membrane protein, Regeneration, Ecosystem, Kavli Institute of Nanoscience, Mass spectrometry, Female, G protein-coupled receptor, Protein, Pharmaceutical industry, Fine chemical, Nature, Chemistry

The paper, for the first time, shows the power of native mass spectrometry in capturing a G protein-coupled receptor (GPCR) signalling cascade in a native membrane environment.

Key Points: 
  • The paper, for the first time, shows the power of native mass spectrometry in capturing a G protein-coupled receptor (GPCR) signalling cascade in a native membrane environment.
  • Native mass spectrometry is a core element of OMass proprietary technology platform, OdyssION, which also integrates novel biochemistry techniques and custom chemistry.
  • Professor Robinson has pioneered the field of mass spectrometry and established it as a method to analyse proteins in their native state.
  • This latest research proposes a new use of native mass spectrometry through the characterization of GPCR targets utilizing native membrane environments as opposed to purified proteins.

OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D

Retrieved on: 
星期一, 二月 28, 2022
Therapy, Muscle, Stomach, GSDMD, Degenerative disease, Pain, Louis-Jeantet Prize for Medicine, Mass, Noise, Familial Mediterranean fever, Lipid, Fever, Biology, Heart, Drug discovery, Medicine, Joint, Mass spectrometry, G protein-coupled receptor, Membrane protein, Ecosystem, Technology, Patent, CEO, Pharmaceutical industry, Vaccine, Fine chemical, Chemistry

OMasss OdyssION Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D

Key Points: 
  • OMasss OdyssION Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D
    Oxford, United Kingdom 28 February 2022 OMass Therapeutics (OMass or the Company), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to provide an update on its proprietary drug discovery platform, OdyssION and its progress in identifying novel medicines against intractable or inadequately drugged membrane and complex-bound proteins.
  • Early data and progress in its gasdermin D program underline the power of the platform.
  • The OdyssION platform allows OMass to interrogate how a protein interacts with its native ecosystem, separate from the confounding complexity of the cell.
  • However, due to the power of the OdyssION platform, OMass has been able to identify a functional hit series.